Core Viewpoint - The company clarifies that its cosmetic sales business, while providing opportunities for commercialization, is currently small in scale compared to its core pharmaceutical business, which focuses on the development and commercialization of KX-826 and GT20029 [1] Group 1: Product and Sales - The product in question is a foam agent for hair loss under the KOSHIN brand, primarily featuring KX-826 as its main ingredient [1] - The company sets a long-term sales target of RMB 100 million, which is cumulative and not expected to be achieved in the short term [1] Group 2: Human Resources - As of the announcement date, the company has 121 employees, with 69 dedicated to drug research and supply, and 24 focused on cosmetic sales and marketing preparations for candidate drugs [1] Group 3: Financials and Funding - R&D expenses are projected to account for over 50% of total expenditures until December 31, 2025, primarily due to funding for KX-826's clinical trials for androgenetic alopecia and GT20029's clinical trials for acne [1] - The board confirms that cash flow from the cosmetic business will be utilized to fund medical and biological applications and development [2] - The company is actively negotiating bank financing expected to be granted in Q1 2026 and is also seeking equity financing from potential investors [2]
开拓药业-B将利用化妆品业务的现金流量为医疗/生物应用及开发提供资金